Allogeneic transplantation represents the most efficient consolidation treatment for most cases of malignant diseases. Some progression was made in the practice of transplantation but still, GvHD, relapse, and infection are the main obstacles. The cumulative incidence of cGvHD by 1 year after transplant ranged from 30-70 %. GvHD is the most common non-relapse mortality (NRM), and accounts of about 10–25 % of all transplanted patients.
CGvHD is defined by the National Institutes of Health (NIH) Consensus depending on clinical manifestations, changing the classical and rather arbitrary chronological “beyond Day 100" definition. There are two types of cGvHD: Classic and overlap. The severity of cGvHD also assessed by the NIH global severity of cGvHD.
Types of Hematopoietic stem-cell transplantation (HSCT) types: Allogeneic or autologous HSC.
Chronic GvHD types: Classic chronic GvHD: occurs at any time after transplantation. Overlap syndrome: May occur at any time after transplantation, with a mixture of features of both cGvHD and aGvHD.
Biomarker Panel for Chronic Graft-Versus-Host Disease:
NIH Biomarker Working Group in 2006 meeting, declared cGvHD biomarkers utilization for clinical trials and disease management in the following conditions to (1) predict the risk of developing cGvHD; (2) diagnose cGvHD ; (3) measure disease activity or predict prognosis; (4) predict therapy response; and (5) serve as the surrogate endpoint for therapeutic response.